ReferenceID 2851
Sesamol Alleviates Obesity-Related Hepatic Steatosis via Activating Hepatic PKA Pathway
Nutrients
This study aimed to investigate the effect of sesamol (SEM) on the protein kinase A (PKA) pathway in obesity-related hepatic steatosis treatment by using high-fat diet (HFD)-induced obese mice and a palmitic acid (PA)-tr
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2851
- Evidence Id
- 19441
- Core Evidence Id
- 19441
- Source Reference Id
- 5689
- Herb2 Reference Id
- HBREF006486
- Subject Paper Key
- HBIN043802_31991934
- Pubmed Id
- 31991934
- Doi
- 10.3390/nu12020329
- Paper Title
- Sesamol Alleviates Obesity-Related Hepatic Steatosis via Activating Hepatic PKA Pathway
- Paper Abstract
- This study aimed to investigate the effect of sesamol (SEM) on the protein kinase A (PKA) pathway in obesity-related hepatic steatosis treatment by using high-fat diet (HFD)-induced obese mice and a palmitic acid (PA)-treated HepG2 cell line. SEM reduced the body weight gain of obese mice and alleviated related metabolic disorders such as insulin resistance, hyperlipidemia, and systemic inflammation. Furthermore, lipid accumulation in the liver and HepG2 cells was reduced by SEM. SEM downregulated the gene and protein levels of lipogenic regulator factors, and upregulated the gene and protein levels of the regulator factors responsible for lipolysis and fatty acid beta-oxidation. Meanwhile, SEM activated AMP-activated protein kinase (AMPK), which might explain the regulatory effect of SEM on fatty acid beta-oxidation and lipogenesis. Additionally, the PKA-C and phospho-PKA substrate levels were higher after SEM treatment. Further research found that after pretreatment with the PKA inhibitor, H89, lipid accumulation was increased even with SEM administration in HepG2 cells, and the effect of SEM on lipid metabolism-related regulator factors was abolished by H89. In conclusion, SEM has a positive therapeutic effect on obesity and obesity-related hepatic steatosis by regulating the hepatic lipid metabolism mediated by the PKA pathway.
- Journal
- Nutrients
- Publish Year
- 2020
- Experiment Subject
- mouse; hepg2 cells; palmitic acid (pa)-treated hepg2 cell line
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Metabolic Disorders; Insulin Resistance; Systemic Inflammation; Hepatic Steatosis; Obesity; Hyperlipidemia; Obese
- Paper Title Cn
- Paper Title En
- Sesamol Alleviates Obesity-Related Hepatic Steatosis via Activating Hepatic PKA Pathway
- Bilingual Status
- semi_complete